Hlk Biotech Holding Stock Net Income
| AMHD Stock | USD 0.0002 0.00 0.00% |
Fundamental analysis of HLK Biotech allows traders to better anticipate movements in HLK Biotech's stock price by examining its financial health and performance throughout various phases of its business cycle.
HLK |
HLK Biotech Holding Company Net Income Analysis
HLK Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current HLK Biotech Net Income | (3.77 K) |
Most of HLK Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HLK Biotech Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, HLK Biotech Holding reported net income of (3,769). This is 100.0% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.0% higher than that of the company.
HLK Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HLK Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of HLK Biotech could also be used in its relative valuation, which is a method of valuing HLK Biotech by comparing valuation metrics of similar companies.HLK Biotech is currently under evaluation in net income category among its peers.
HLK Fundamentals
| Return On Asset | -0.97 | |||
| Revenue | 8.33 K | |||
| Gross Profit | (180 K) | |||
| EBITDA | (701.16 K) | |||
| Net Income | (3.77 K) | |||
| Cash And Equivalents | 185.72 K | |||
| Total Debt | 600 K | |||
| Current Ratio | 0.16 X | |||
| Cash Flow From Operations | (1.21 K) | |||
| Beta | 1.99 | |||
| Market Capitalization | 462.46 K | |||
| Total Asset | 116.71 K | |||
| Z Score | -19.8 | |||
| Net Asset | 116.71 K |
About HLK Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HLK Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HLK Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HLK Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in HLK Pink Sheet
HLK Biotech financial ratios help investors to determine whether HLK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLK with respect to the benefits of owning HLK Biotech security.